1. Home
  2. WAY vs GH Comparison

WAY vs GH Comparison

Compare WAY & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WAY
  • GH
  • Stock Information
  • Founded
  • WAY 1999
  • GH 2011
  • Country
  • WAY United States
  • GH United States
  • Employees
  • WAY N/A
  • GH N/A
  • Industry
  • WAY
  • GH Medical Specialities
  • Sector
  • WAY
  • GH Health Care
  • Exchange
  • WAY Nasdaq
  • GH Nasdaq
  • Market Cap
  • WAY 5.3B
  • GH 4.3B
  • IPO Year
  • WAY 2024
  • GH 2018
  • Fundamental
  • Price
  • WAY $35.76
  • GH $34.75
  • Analyst Decision
  • WAY Strong Buy
  • GH Strong Buy
  • Analyst Count
  • WAY 10
  • GH 15
  • Target Price
  • WAY $33.22
  • GH $39.93
  • AVG Volume (30 Days)
  • WAY 1.4M
  • GH 1.5M
  • Earning Date
  • WAY 02-10-2025
  • GH 11-06-2024
  • Dividend Yield
  • WAY N/A
  • GH N/A
  • EPS Growth
  • WAY N/A
  • GH N/A
  • EPS
  • WAY N/A
  • GH N/A
  • Revenue
  • WAY $906,142,000.00
  • GH $692,256,000.00
  • Revenue This Year
  • WAY $18.69
  • GH $32.23
  • Revenue Next Year
  • WAY $7.68
  • GH $16.90
  • P/E Ratio
  • WAY N/A
  • GH N/A
  • Revenue Growth
  • WAY 18.23
  • GH 29.20
  • 52 Week Low
  • WAY $20.26
  • GH $15.81
  • 52 Week High
  • WAY $35.98
  • GH $38.53
  • Technical
  • Relative Strength Index (RSI)
  • WAY N/A
  • GH 58.28
  • Support Level
  • WAY N/A
  • GH $34.20
  • Resistance Level
  • WAY N/A
  • GH $36.24
  • Average True Range (ATR)
  • WAY 0.00
  • GH 1.40
  • MACD
  • WAY 0.00
  • GH -0.54
  • Stochastic Oscillator
  • WAY 0.00
  • GH 12.70

About WAY Waystar Holding Corp. Common Stock

Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in better transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for our solutions extends throughout the United States and includes Puerto Rico and other US Territories.

About GH Guardant Health Inc.

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: